Evidence map›Paper›PMID 33807817›Full record

ArticleCells2021

Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased

Benita C Percival, Yvonne L Latour, Cynthia J Tifft, Martin Grootveld

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Benita C PercivalLeicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK.
Yvonne L LatourDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN 37232-0252, USA.
Cynthia J TifftDeputy Clinical Director, National Human Genome Research Institute, Director, National Institutes of Health, Bethesda, MD 20892-1205, USA.
Martin GrootveldLeicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK.ORCID 0000-0003-1502-3734
De Montfort University · GBNational Institutes of Health · USVanderbilt University · US

Funding

Pathogenesis informs therapy in the GM1 and GM2 GangliosidosesZIAHG200409 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI TIFFT, CYNTHIA · 2020 to 2025
$4.1M
National Tay-Sachs and Allied Diseases Association (NTSAD), Boston, MA 02135, USA NTSAD_DMUMG1
6 · The paper itself

Abstract

Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of GM1 gangliosidosis type 2 (GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for this disorder, we employed an untargeted, multi-analyte approach involving high-resolution

Indexed as

BiomarkersFemaleGangliosidosis, GM1G(M1) GangliosideHumansMagnetic Resonance ImagingMaleMetabolomicsBiomarkersG(M1) GangliosidebiomarkersGM1 gangliosidosislysosomal storage disordersmetabolite set enrichment analysisNMR-based metabolomicsnuclear magnetic resonance (NMR) analysisvalidation

Identifiers

PMID33807817
PMCPMC7998791
OpenAlexW3134018095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.